Heart Disease Risk Study in Adults Aged 40 to 69 Newly Diagnosed with Type 2 Diabetes in Southeast Asia

What this Trial Is About

Researchers are investigating the cardiovascular disease CVD risk profile among adults newly diagnosed with type 2 diabetes mellitus T2DM in Southeast Asia. This observational study uses retrospective chart reviews from five Southeast Asian countries to understand how CVD risk is distributed in these patients, based on data from the year before diagnosis and about the first year after diagnosis. The study focuses on adults aged 40 to 69 years who have recently started anti-hyperglycemic treatment. Participants are identified based on their diagnosis of T2DM between January 2022 and December 2023. The study does not involve any treatment administration as it is observational, relying on existing health records. Researchers collect data on cardiometabolic profiles at baseline, including measurements such as blood pressure, waist and hip circumference, height, weight, cholesterol levels, blood sugar levels, kidney function markers, and classification into CVD risk categories. During the study, participants medical records are reviewed to gather baseline measurements at the index date or within the previous 12 months if unavailable on the index date. The main outcomes measured include systolic blood pressure, lipid profiles, glycated hemoglobin, fasting glucose, kidney function tests, and CVD risk categorization. The study tracks participants health status for up to one year following their diagnosis to analyze cardiovascular risk factors and outcomes.

A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants